MemorialCare Innovation Fund contributed to a series D round that brought the heart valve technology developer's overall funding to more than $36m.

MemorialCare Innovation Fund contributed to a series D round that brought the Caltech spinout's overall funding to more than $36m.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.

Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Ona Therapeutics is working on treatments for metastatic cancer and has collected series A funding from investors including Bpifrance.

Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

The series C round consisted of $77m in equity funding and $25m in venture debt, with Kaiser Permanente among the participants.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.